These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 12171482

  • 1. Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization.
    Nash RA, Takatu A, Feng Z, Slichter S, Abrams K, Espino G, Gass MJ, Georges GE, McSweeney PA, Shulman HM, Storb R.
    Biol Blood Marrow Transplant; 2002; 8(7):360-7. PubMed ID: 12171482
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation.
    Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R.
    Biol Blood Marrow Transplant; 2000; 6(1):25-34. PubMed ID: 10707996
    [Abstract] [Full Text] [Related]

  • 3. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.
    Wolff SN, Herzig R, Lynch J, Ericson SG, Greer JP, Stein R, Goodman S, Benyunes MC, Ashby M, Jones DV, Fay J.
    Bone Marrow Transplant; 2001 Feb; 27(3):261-8. PubMed ID: 11277173
    [Abstract] [Full Text] [Related]

  • 5. Lack of efficacy of thrombopoietin and granulocyte colony-stimulating factor after high dose total-body irradiation and autologous stem cell or bone marrow transplantation in rhesus monkeys.
    Neelis KJ, Dubbelman YD, Wognum AW, Thomas GR, Eaton DL, Egeland T, Wagemaker G.
    Exp Hematol; 1997 Sep; 25(10):1094-103. PubMed ID: 9293907
    [Abstract] [Full Text] [Related]

  • 6. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM, MacVittie TJ, Roskos L, Stead RB.
    Stem Cells; 2003 Sep; 21(1):79-89. PubMed ID: 12529554
    [Abstract] [Full Text] [Related]

  • 7. Single-Dose Administration of Recombinant Human Thrombopoietin Mitigates Total Body Irradiation-Induced Hematopoietic System Injury in Mice and Nonhuman Primates.
    Xing S, Shen X, Yang JK, Wang XR, Ou HL, Zhang XW, Xiong GL, Shan YJ, Cong YW, Luo QL, Yu ZY.
    Int J Radiat Oncol Biol Phys; 2020 Dec 01; 108(5):1357-1367. PubMed ID: 32758640
    [Abstract] [Full Text] [Related]

  • 8. Sequential treatment with rmIL-3 or simultaneous treatment with rmIL-3 or rhIL-11 with thrombopoietin (TPO) fails to enhance in vivo neonatal rat thrombocytopoiesis.
    van de Ven C, Fernandez GW, Herbst T, Knoppel A, Cairo MS.
    Exp Hematol; 1997 Aug 01; 25(9):1005-12. PubMed ID: 9257814
    [Abstract] [Full Text] [Related]

  • 9. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul 01; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 10. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H.
    Blood; 1998 Jan 01; 91(1):37-45. PubMed ID: 9414267
    [Abstract] [Full Text] [Related]

  • 11. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB.
    Blood; 1997 Jan 01; 89(1):155-65. PubMed ID: 8978288
    [Abstract] [Full Text] [Related]

  • 12. Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.
    Fu A, Peng Y, Cheng P, Wu J, Zhu X, Yang Y, Huang L, Wang N, Wang J, Xu J, Wan Y, Cao Y, Wei J, Xiao Y, Meng F, Cheng H, Zhang Y, Zhang D.
    Transplant Cell Ther; 2024 May 01; 30(5):500-509. PubMed ID: 38447750
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.
    Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W, Fay J, Lynch JP, Goodnough LT, Ashby M, Benyunes MC, Jones DV, Yang TA, Miller LL, Weaver C.
    Biol Blood Marrow Transplant; 2003 Jun 01; 9(6):405-13. PubMed ID: 12813449
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT.
    Cao Y, Wang M, Shen B, Zhao F, Zhang R, Chen X, He Y, Zhai W, Ma Q, Wei J, Huang Y, Yang D, Pang A, Feng S, Jiang E, Han M.
    Clin Appl Thromb Hemost; 2022 Jun 01; 28():10760296211068037. PubMed ID: 35019756
    [Abstract] [Full Text] [Related]

  • 15. [Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation].
    Song Y, Zhou F, Song NX, Liu XM, Yu Z, Xie LN, Song XC, Li X.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Mar 14; 39(3):207-211. PubMed ID: 29562465
    [Abstract] [Full Text] [Related]

  • 16. Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation.
    Schuening FG, Appelbaum FR, Deeg HJ, Sullivan-Pepe M, Graham TC, Hackman R, Zsebo KM, Storb R.
    Blood; 1993 Jan 01; 81(1):20-6. PubMed ID: 7678065
    [Abstract] [Full Text] [Related]

  • 17. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.
    Bone Marrow Transplant; 1996 Dec 01; 18(6):1035-41. PubMed ID: 8971370
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
    Nakamura M, Toombs CF, Duarte IG, Ronson RS, Schmarkey LS, Katzmark SL, Robinson J, Dillehay DL, Vinten-Johansen J, Guyton RA.
    Ann Thorac Surg; 1998 Oct 01; 66(4):1216-23. PubMed ID: 9800809
    [Abstract] [Full Text] [Related]

  • 19. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.
    Blood; 1996 Jul 15; 88(2):511-21. PubMed ID: 8695799
    [Abstract] [Full Text] [Related]

  • 20. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.